Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1

Conditions

Multiple Myeloma 129Recurrence 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasms, Plasma Cell 15Neoplasms 12Lymphoma, Non-Hodgkin 12Lymphoma 12Leukemia, Myeloid, Acute 10Lymphoma, Large B-Cell, Diffuse 9Neoplasm Metastasis 8Leukemia 8Burkitt Lymphoma 8Immunoglobulin Light-chain Amyloidosis 7Hodgkin Disease 7Prostatic Neoplasms 6Leukemia, Biphenotypic, Acute 5Lymphoma, B-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Hematologic Diseases 3Colorectal Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 2Sarcoma 2Rectal Neoplasms 2

Interventions

Dexamethasone 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1filanesib 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Steroids 1Specimen Handling 1Sodium Selenite 1Radiotherapy 1Radiation 1Proteasome Inhibitors 1Lenalidomide 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Calcium Dobesilate 1Bortezomib 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Plasmacytoma × Dexamethasone × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡